Analysis of the key themes driving M&A activity reveals that ecommerce accounted for eight pharmaceutical deals announced in Q3 2024, worth a total value of $1.3bn. The $924m acquisition of Revance Therapeutics by Crown Laboratories was the industry’s largest disclosed deal. GlobalData’s Pharmaceuticals Industry Mergers and Acquisitions Deals by Top Themes report for Q3 2024 dissects the driving forces behind the M&A dynamics within the Pharma sector, offering essential insights into industry trends and transformations. Buy the report here.
In value terms, ecommerce-related deal activity increased by 259900% in Q3 2024 compared with the previous quarter’s total of $0.5m and rose by 899% as compared to Q3 2023. Related deal volume decreased by 11% in Q3 2024 versus the previous quarter and was 60% higher than in Q3 2023.
The top-ranked financial advisors supporting these M&A deals in 9M 2024 were EC Mergers & Acquisitions; Northbound Group; PJT Partners with 1, 1, 1 deals respectively.
The top-ranked legal advisors supporting these M&A deals in 9M 2024 were Kirkland & Ellis; Skadden, Arps, Slate, Meagher & Flom LLP & Affiliates; Weil, Gotshal & Manges with 2, 2, 2 deals respectively.
For further understanding of GlobalData's Pharmaceuticals Industry M&A Deals by Top Themes in Q3 2024 – Strategic Intelligence, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.